All Dr Philipp Jost (scientific founder and Managing Director - Cycuria Therapeutics) articles

  • Acute,Myeloid,Leukemia,(aml),Cells,In,Blood,Flow,-,Closeup
    Article

    Targeting inflammatory cell death to tackle relapse in AML

    2026-01-22T09:00:33Z

    Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.